Premium
Carbohydrate‐based particles reduce allergic inflammation in a mouse model for cat allergy
Author(s) -
NeimertAndersson T.,
Thunberg S.,
Swedin L.,
Wiedermann U.,
JacobssonEkman G.,
Dahlén S.E.,
Scheynius A.,
Grönlund H.,
Hage M. van,
Gafvelin G.
Publication year - 2008
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2008.01644.x
Subject(s) - immunology , allergen , immunoglobulin e , adjuvant , allergy , medicine , splenocyte , bronchoalveolar lavage , nasal administration , allergic inflammation , aeroallergen , inflammation , immunotherapy , antibody , immune system , lung
Background: Allergen‐specific immunotherapy (ASIT) is the only treatment of allergic disease that gives long‐lasting relief of symptoms. However, concerns for safety and efficiency have highlighted the need for improvement of the therapy. We have previously suggested carbohydrate‐based particles (CBPs) as a novel adjuvant and allergen carrier for ASIT. Our aim of this study was to evaluate the therapeutic potential of CBPs in ASIT, employing a mouse model for cat allergy. Methods: BALB/c mice were subcutaneously immunized with the recombinant (r) cat allergen Fel d 1 followed by intranasal challenge with cat dander extract (CDE). The sensitized mice were therapeutically treated with rFel d 1 covalently coupled to CBPs (CBP‐rFel d 1). Airway hyper‐reactivity (AHR), infiltration of leucocytes in bronchoalveolar lavage (BAL) fluid, allergen‐specific serum immunoglobulin levels and in vitro splenocyte responses were evaluated. Results: Mice treated with CBP‐rFel d 1 showed reduced features of allergic inflammation. They responded with (i) significantly decreased AHR and infiltration of eosinophils in BAL fluid after CDE challenge, (ii) the serum level of rFel d 1‐specific IgE was reduced and the level of IgG 2 a was more pronounced after CBP‐rFel d 1 treatment, and (iii) there was also a tendency of decreased allergen‐specific cellular response. Conclusions: Carbohydrate‐based particles are effective tools as adjuvant and allergen carriers for use in ASIT and constitutes a promising strategy to improve allergy treatment.